Verona Pharma plc (NASDAQ:VRNA) Q1 2022 Earnings Conference Call May 3, 2022 9:00 AM ET

Company Representatives

Dr. David Zaccardelli - Chief Executive Officer

Mark Hahn - Chief Financial Officer

Dr. Kathy Rickard - Chief Medical Officer

Chris Martin - Senior Vice President of Commercial

Conference Call Participants

Suji Jeong - Jefferies

Andreas Argyrides - Wedbush Securities

Boobalan Pachaiyappan - H.C. Wainwright

Edward Nash - Canaccord Genuity

Joon Lee - Truist Securities

Operator

Welcome to Verona Pharma's, First Quarter 2022 Financial Results and Operating Highlights Conference Call. At this time all participants are in a listen-only mode. [Operator Instructions] Earlier this morning Verona Pharma issued a press release announcing its financial results for the three months ended March 31, 2022. A copy can be found in the Investor Relations tab on the corporate website www.veronapharma.com.

Before we begin, I'd like to remind you that during today's call, statements about the company's future expectations, plans and prospects are forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations, expressed or implied by the forward-looking statements, including, without limitation, the impact of the COVID-19 pandemic and the Russia, Ukraine conflict on such progress, and on the status, recruitment, timing, results and costs of our clinical trials.

Any such forward-looking statements represent management's estimates as of the date of this conference call. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligations to do so, even if subsequent events cause its views to change.

After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions]. As a reminder, this call is being recorded and will remain available for 90 days.

I’d now like to turn the call over to Dr. David Zaccardelli, Chief Executive Officer. Please go ahead.

David Zaccardelli

Thank you, and welcome everyone to today's call. With me today are Mark Hahn, our Chief Financial Officer; Dr. Kathy Rickard, our Chief Medical Officer; and Chris Martin, our Senior Vice President of Commercial.

During the first quarter of 2022 we continue to make substantial progress toward completing enrollment in our Phase 3 ENHANCE clinical program. This advancement brings us closer to our goal of delivering ensifentrine, a novel inhaled PDE3 and PDE4 inhibitor and first in class product candidate for the maintenance treatment of COPD.